Recherche
Enseignement
Solutions
S'identifier
FR
EN - English
CN - 中文
DE - Deutsch
ES - Español
KR - 한국어
IT - Italiano
FR - Français
PT - Português
TR - Turkish
JA - Japanese
Istituto di Patologia Generale,
Dipartimento di Medicina e Chirurgia Traslazionale
Martina Musella has not added Biography.
If you are Martina Musella and would like to personalize this page please email our Author Liaison for assistance.
IFN-α potentiates the direct and immune-mediated antitumor effects of epigenetic drugs on both metastatic and stem cells of colorectal cancer.
Oncotarget May, 2016 | Pubmed ID: 27028869
Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications.
Oncoimmunology , 2017 | Pubmed ID: 28638743
Assessment of IFN-γ and granzyme-B production by in "sitro" technology.
Methods in enzymology , 2020 | Pubmed ID: 31948559
Cytofluorometric assessment of dendritic cell-mediated uptake of cancer cell apoptotic bodies.
Methods in enzymology , 2020 | Pubmed ID: 32000907
Tuning Cancer Fate: Tumor Microenvironment's Role in Cancer Stem Cell Quiescence and Reawakening.
Frontiers in immunology , 2020 | Pubmed ID: 33193295
Control of replication stress and mitosis in colorectal cancer stem cells through the interplay of PARP1, MRE11 and RAD51.
Cell death and differentiation Feb, 2021 | Pubmed ID: 33531658
The Targeting of MRE11 or RAD51 Sensitizes Colorectal Cancer Stem Cells to CHK1 Inhibition.
Cancers Apr, 2021 | Pubmed ID: 33921638
The Yin and Yang of Type I IFNs in Cancer Promotion and Immune Activation.
Biology Sep, 2021 | Pubmed ID: 34571733
Actin Cytoskeleton Dynamics and Type I IFN-Mediated Immune Response: A Dangerous Liaison in Cancer?
Biology Sep, 2021 | Pubmed ID: 34571790
The Immune Privilege of Cancer Stem Cells: A Key to Understanding Tumor Immune Escape and Therapy Failure.
Cells Sep, 2021 | Pubmed ID: 34572009
Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B.
Nature immunology Sep, 2022 | Pubmed ID: 36002648
3D cancer models: One step closer to human studies.
Frontiers in immunology , 2023 | Pubmed ID: 37114038
Epigenetics behind tumor immunology: a mini review.
Oncogene Sep, 2023 | Pubmed ID: 37604925
Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment in pancreatic cancer.
Journal of translational medicine Nov, 2023 | Pubmed ID: 37996891
In Vitro Evaluation of Cancer Cell Immunogenicity and Antigen-Specific T-Cell Cytotoxicity by Flow Cytometry.
Methods in molecular biology (Clifton, N.J.) , 2024 | Pubmed ID: 38070104
Università Cattolica del Sacro Cuore
Adele De Ninno1,
Francesca Romana Bertani1,
Annamaria Gerardino1,
Giovanna Schiavoni2,
Martina Musella3,
Claudia Galassi3,
Fabrizio Mattei2,
Antonella Sistigu3,4,
Luca Businaro1
1, CNR Institute for Photonics and Nanotechnology,
2Dept. of Oncology and Molecular Medicine, Istituto Superiore di Sanità,
3Istituto di Patologia Generale, Università Cattolica del Sacro Cuore,
4Tumor Immunology and Immunotherapy Unit, IRCCS Regina Elena National Cancer Institute
Nicoletta Manduca*,1,
Ester Maccafeo*,1,
Adele De Ninno2,
Antonella Sistigu1,3,
Martina Musella1
1Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore,
2, CNR Institute for Photonics and Nanotechnology,
3, Fondazione Policlinico Universitario ‘A. Gemelli’ - IRCCS
Confidentialité
Conditions d'utilisation
Politiques
Contactez-nous
RECOMMANDER À LA BIBLIOTHÈQUE
NEWSLETTERS JoVE
JoVE Journal
Collections de méthodes
JoVE Encyclopedia of Experiments
Archives
JoVE Core
JoVE Business
JoVE Science Education
JoVE Lab Manual
Centre de ressources universitaires
Auteurs
Bibliothécaires
Accès
À PROPOS DE JoVE
Copyright © 2024 MyJoVE Corporation. Tous droits réservés.